TABLE 1

Demographic information for all patients and those at GINA step 4 and step 5 of treatment

AllGINA step 4GINA step 5
Subjects n160#10059
Female107 (66)67 (67)40 (67)
Age years51 (16–78)49 (16–74)55 (25–78)
FEV1 L2.0 (0.7–4.4)2.2 (0.72–4.3)1.8 (0.7–3.6)
FEV1 % predicted72 (28–137)75 (28–137)65 (34–107)
Caucasian %98
BMI kg·m−231.8 (18.2–58.3)31.0 (19.0–58.3)33.3 (20.7–57.9)
Median ICS dose BDP equivalent μg·day−11600 (400–4000)1600 (800–4000)2000 (1000–4000)
Taking biologics
 Omalizumab34 (21)
 Mepolizumab4 (3)

Data are presented as n (range) or n (%), unless otherwise stated. GINA: Global Initiative for Asthma; FEV1: forced expiratory volume in 1 s; BMI: body mass index; ICS: inhaled corticosteroid; BDP: beclomethasone dipropionate. #: one patient at GINA step 2 was included erroneously but included in the intention-to-treat analysis, see Results section.